Daratumumab Treatment in Severe Anti-NMDAR Encephalitis

Abstract

Objectives To describe clinical outcomes following daratumumab therapy in severe anti–N-methyl-d-aspartate receptor (NMDAR) encephalitis, including a literature review. Methods We report 2 patients with severe anti-NMDAR encephalitis treated with anti-CD38 daratumumab after failure of multiple immunotherapies. Clinical data, treatments, and outcomes were analyzed retrospectively. A PubMed literature review identified 4 additional cases. Results Both patients (21 and 19 years) presented with severe anti-NMDAR encephalitis characterized by neuropsychiatric symptoms, seizures, abnormal movements, and dysautonomia. Modified Rankin Scale (mRS) reached rapidly 5 in both cases and required ICU transfer within the first 2 weeks of hospitalization. Despite high-dose methylprednisolone, IV immunoglobulin, plasma exchange, rituximab, and cyclophosphamide, neither patient showed improvement. Daratumumab (1800 mg s/c) was initiated 40 and 14 weeks after onset, respectively. Clinical improvement occurred within weeks after treatment initiation, with gradual recovery of cognitive and functional abilities and ultimately regained functional independence (mRS 0). Literature review identified 4 additional cases of anti-NMDAR encephalitis treated with daratumumab; most patients showed substantial neurologic improvement. Discussion These observations suggest that specific plasma cell–targeted therapy may be beneficial in severe anti-NMDAR encephalitis, potentially through reduction of pathogenic autoantibody production. However, current evidence is limited to uncontrolled reports, and further studies are needed to clarify optimal timing, efficacy, and safety.